{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:57:47Z","timestamp":1786971467138,"version":"build-2736575974"},"reference-count":130,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n<jats:title>Background and Objective:<\/jats:title>\n<jats:p>Parkinson's disease (PD) is a neurodegenerative disorder characterized\nby the degeneration of the dopaminergic neurons in the substantia nigra pars compacta, resulting\nin the loss of dopamine in the striatum, leading thus to the PD classic movement symptoms:\nresting tremor, rigidity, and bradykinesia\/akinesia. Furthermore, Levodopa\u2019s efficacy declines with\nlong-term use, generating serious motor complications. Neuroprotection implies the use of different\nagents exhibiting various neuroprotective strategies to prevent brain degeneration and neuron loss. The\npresent review aims to summarize and analyze the natural neuroprotective compounds that have been\ntested against PD induced by the 6-hydroxydopamine (6-OHDA) in zebrafish.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The current study collected 23 different natural substances, divided into five distinct categories,\nnamely herbal extracts, herbal formulations, bioactive compounds, marine products, and marine\nextracts. They modulate various signaling pathways involved in PD pathogenesis and exhibit specific\nactivities such as an anxiolytic profile, improving locomotor impairment, restoring memory troubles,\npreventing DNA loss, inhibiting acetylcholinesterase, reducing lipid peroxidation and antiinflammatory\nactivity, and enhancing the brain antioxidant enzymes.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion and Perspectives:<\/jats:title>\n<jats:p>This review discusses the most promising natural neuroprotective compounds\nthat have been evaluated for their potential efficiency on the 6-OHDA-induced lesions in the\nzebrafish model. These natural substances deserve further consideration for determination of their optimum\nconcentrations, bioavailability, and their ability to cross the blood-brain-barrier to exert their\neffects on PD. Furthermore, a complete understanding of the molecular mechanisms involved in PD\nand larger epidemiologic and randomized clinical trials in humans is also required.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527322666221028152600","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:18:15Z","timestamp":1666984695000},"page":"1472-1483","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Natural Neuroprotective Compounds Used in the 6-Hydroxydopamine-\nInduced Parkinson\u2019s Disease in Zebrafish: The Current\nApplications and Perspectives"],"prefix":"10.2174","volume":"22","author":[{"given":"Sara","family":"Abidar","sequence":"first","affiliation":[{"name":"Laboratory of Biochemistry and Molecular Genetics (LBMG), Faculty of Sciences and Technologies of Tangier\n(FSTT) Abdelmalek Essaadi University, Tetouan, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Hritcu","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Biology, Alexandru\nIoan Cuza University of Iasi, Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Nhiri","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry and Molecular Genetics (LBMG), Faculty of Sciences and Technologies of Tangier\n(FSTT) Abdelmalek Essaadi University, Tetouan, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"Dexter D.T.","year":"2013","unstructured":"Dexter D.T.; Jenner P.; Parkinson disease: From pathology to molecular disease mechanisms. Free Radic Biol Med 2013,62,132-144","journal-title":"Free Radic Biol Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"Pringsheim T.","year":"2014","unstructured":"Pringsheim T.; Jette N.; Frolkis A.; Steeves T.D.L.; The prevalence of Parkinson\u2019s disease: A systematic review and meta-analysis. Mov Disord 2014,29(13),1583-1590","journal-title":"Mov Disord"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3111\/13696998.2012.737392","volume":"16","author":"Valldeoriola F.","year":"2013","unstructured":"Valldeoriola F.; Puig-Junoy J.; Puig-Peir\u00f3 R.; Cost analysis of the treatments for patients with advanced Parkinson\u2019s disease: SCOPE study. J Med Econ 2013,16(2),191-201","journal-title":"J Med Econ"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00415-010-5717-y","volume":"257","author":"Gershanik O.S.","year":"2010","unstructured":"Gershanik O.S.; Clinical problems in late-stage Parkinson\u2019s disease. J Neurol 2010,257(S2),288-291","journal-title":"J Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"Dorsey E.R.","year":"2018","unstructured":"Dorsey E.R.; Elbaz A.; Nichols E.; Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018,17(11),939-953","journal-title":"Lancet Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3111\/13696998.2010.551164","volume":"14","author":"Findley L.J.","year":"2011","unstructured":"Findley L.J.; Wood E.; Lowin J.; Roeder C.; Bergman A.; Schifflers M.; The economic burden of advanced Parkinson\u2019s disease: An analysis of a UK patient dataset. J Med Econ 2011,14(1),130-139","journal-title":"J Med Econ"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.parkreldis.2009.07.005","volume":"16","author":"Winter Y.","year":"2010","unstructured":"Winter Y.; von Campenhausen S.; Brozova H.; Costs of Parkinson\u2019s disease in Eastern Europe: A czech cohort study. Parkinsonism Relat Disord 2010,16(1),51-56","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000302644","volume":"7","author":"Winter Y.","year":"2010","unstructured":"Winter Y.; von Campenhausen S.; Reese J.P.; Costs of Parkinson\u2019s disease and antiparkinsonian pharmacotherapy: An Italian cohort study. Neurodegener Dis 2010,7(6),365-372","journal-title":"Neurodegener Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1474-4422(16)00116-2","volume":"15","author":"Postuma R.B.","year":"2016","unstructured":"Postuma R.B.; Berg D.; Adler C.H.; The new definition and diagnostic criteria of Parkinson\u2019s disease. Lancet Neurol 2016,15(6),546-548","journal-title":"Lancet Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.neuroscience.2011.08.045","volume":"198","author":"Surmeier D.J.","year":"2011","unstructured":"Surmeier D.J.; Guzman J.N.; Sanchez-Padilla J.; Schumacker P.T.; The role of calcium and mitochondrial oxidant stress in the loss of sub-stantia nigra pars compacta dopaminergic neurons in Parkinson\u2019s disease. Neuroscience 2011,198,221-231","journal-title":"Neuroscience"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11064-011-0619-7","volume":"37","author":"Venkateshappa C.","year":"2012","unstructured":"Venkateshappa C.; Harish G.; Mythri R.B.; Mahadevan A.; Srinivas Bharath M.M.; Shankar S.K.; Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: Implications for Parkinson\u2019s disease. Neurochem Res 2012,37(2),358-369","journal-title":"Neurochem Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","volume":"18","author":"Hirsch E.C.","year":"2012","unstructured":"Hirsch E.C.; Vyas S.; Hunot S.; Neuroinflammation in Parkinson\u2019s disease. Parkinsonism Relat Disord 2012,18(S1),S210-S212","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Tong Q.; Ma S.R.; Oral berberine improves brain dopa\/dopamine levels to ameliorate Parkinson\u2019s disease by regulating gut microbiota. Signal Transduct Target Ther 2021,6,1-20","journal-title":"Signal Transduct Target Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"Martinez-Martin P.","year":"2011","unstructured":"Martinez-Martin P.; Rodriguez-Blazquez C.; Kurtis M.M.; Chaudhuri K.R.; The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease. Mov Disord 2011,26(3),399-406","journal-title":"Mov Disord"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"Seppi K.","year":"2011","unstructured":"Seppi K.; Weintraub D.; Coelho M.; The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord 2011,26(S3),S42-S80","journal-title":"Mov Disord"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11940-011-0121-1","volume":"13","author":"Kurtz A.L.","year":"2011","unstructured":"Kurtz A.L.; Kaufer D.I.; Dementia in Parkinson\u2019s disease. Curr Treat Options Neurol 2011,13(3),242-254","journal-title":"Curr Treat Options Neurol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.nbd.2012.03.029","volume":"46","author":"Pagonabarraga J.","year":"2012","unstructured":"Pagonabarraga J.; Kulisevsky J.; Cognitive impairment and dementia in Parkinson\u2019s disease. Neurobiol Dis 2012,46(3),590-596","journal-title":"Neurobiol Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.neuint.2012.12.016","volume":"62","author":"Taylor J.M.","year":"2013","unstructured":"Taylor J.M.; Main B.S.; Crack P.J.; Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson\u2019s disease. Neurochem Int 2013,62(5),803-819","journal-title":"Neurochem Int"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","volume":"34","author":"Games D.","year":"2014","unstructured":"Games D.; Valera E.; Spencer B.; Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models. J Neurosci 2014,34(28),9441-9454","journal-title":"J Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"Sampson T.R.","year":"2016","unstructured":"Sampson T.R.; Debelius J.W.; Thron T.; Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson\u2019s disease. Cell 2016,167(6),1469-1480.e12","journal-title":"Cell"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11481-014-9569-6","volume":"10","author":"Gonz\u00e1lez-Burgos E.","year":"2015","unstructured":"Gonz\u00e1lez-Burgos E.; Fernandez-Moriano C.; G\u00f3mez-Serranillos M.P.; Potential neuroprotective activity of Ginseng in Parkinson\u2019s disease: A review. J Neuroimmune Pharmacol 2015,10(1),14-29","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1326-4-24","volume":"4","author":"Malkus K.A.","year":"2009","unstructured":"Malkus K.A.; Tsika E.; Ischiropoulos H.; Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkin-son\u2019s disease: How neurons are lost in the Bermuda triangle. Mol Neurodegener 2009,4(1),24","journal-title":"Mol Neurodegener"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.parkreldis.2012.04.030","volume":"18","author":"Cho S.Y.","year":"2012","unstructured":"Cho S.Y.; Shim S.R.; Rhee H.Y.; Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson\u2019s disease. Parkinsonism Relat Disord 2012,18(8),948-952","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms17060904","volume":"17","author":"Sarkar S.","year":"2016","unstructured":"Sarkar S.; Raymick J.; Imam S.; Neuroprotective and therapeutic strategies against Parkinson\u2019s disease: Recent perspectives. Int J Mol Sci 2016,17(6),904","journal-title":"Int J Mol Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","volume":"75","author":"M\u00fcller T.","year":"2015","unstructured":"M\u00fcller T.; Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease. Drugs 2015,75(2),157-174","journal-title":"Drugs"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mds.25108","volume":"28","author":"Bezard E.","year":"2013","unstructured":"Bezard E.; Yue Z.; Kirik D.; Spillantini M.G.; Animal models of Parkinson\u2019s disease: Limits and relevance to neuroprotection studies. Mov Disord 2013,28(1),61-70","journal-title":"Mov Disord"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coph.2015.10.006","volume":"26","author":"Olson K.E.","year":"2016","unstructured":"Olson K.E.; Gendelman H.E.; Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson\u2019s disease. Curr Opin Pharmacol 2016,26,87-95","journal-title":"Curr Opin Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.foodres.2011.10.008","volume":"45","author":"Sekeroglu N.","year":"2012","unstructured":"Sekeroglu N.; Senol F.S.; Orhan I.E.; Gulpinar A.R.; Kartal M.; Sener B.; In vitro prospective effects of various traditional herbal coffees con-sumed in Anatolia linked to neurodegeneration. Food Res Int 2012,45(1),197-203","journal-title":"Food Res Int"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.expneurol.2012.02.012","volume":"235","author":"Decressac M.","year":"2012","unstructured":"Decressac M.; Mattsson B.; Bj\u00f6rklund A.; Comparison of the behavioural and histological characteristics of the 6-OHDA and \u03b1-synuclein rat models of Parkinson\u2019s disease. Exp Neurol 2012,235(1),306-315","journal-title":"Exp Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbr.2010.09.027","volume":"217","author":"Richetti S.K.","year":"2011","unstructured":"Richetti S.K.; Blank M.; Capiotti K.M.; Quercetin and rutin prevent scopolamine-induced memory impairment in zebrafish. Behav Brain Res 2011,217(1),10-15","journal-title":"Behav Brain Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fgene.2014.00189","volume":"5","author":"Newman M.","year":"2014","unstructured":"Newman M.; Ebrahimie E.; Lardelli M.; Using the zebrafish model for Alzheimer\u00e2\u20ac\u2122s disease research. Front Genet 2014,5,189","journal-title":"Front Genet"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.brainres.2010.02.031","volume":"1328","author":"Khan M.M.","year":"2010","unstructured":"Khan M.M.; Ahmad A.; Ishrat T.; Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson\u2019s disease. Brain Res 2010,1328,139-151","journal-title":"Brain Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1749-8546-6-16","volume":"6","author":"Wang M.","year":"2011","unstructured":"Wang M.; Zhang Z.; Cheang L.C.V.; Lin Z.; Lee S.M.Y.; Eriocaulon buergerianum extract protects PC12 cells and neurons in zebrafish against 6-hydroxydopamine-induced damage. Chin Med 2011,6(1),16","journal-title":"Chin Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.redox.2016.10.019","volume":"11","author":"Zhang C.","year":"2017","unstructured":"Zhang C.; Li C.; Chen S.; Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K\/AKT\/Bcl-2 and Nrf2\/HO-1 pathways. Redox Biol 2017,11,1-11","journal-title":"Redox Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2010.05.010","volume":"40","author":"Panula P.","year":"2010","unstructured":"Panula P.; Chen Y.C.; Priyadarshini M.; The comparative neuroanatomy and neurochemistry of zebrafish CNS systems of relevance to human neuropsychiatric diseases. Neurobiol Dis 2010,40(1),46-57","journal-title":"Neurobiol Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"41082","DOI":"10.1038\/srep41082","volume":"7","author":"Zhang C.","year":"2017","unstructured":"Zhang C.; Li C.; Chen S.; Hormetic effect of panaxatriol saponins confers neuroprotection in PC12 cells and zebrafish through PI3K\/AKT\/mTOR and AMPK\/SIRT1\/FOXO3 pathways. Sci Rep 2017,7(1),41082","journal-title":"Sci Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jep.2011.12.030","volume":"139","author":"Song J.X.","year":"2012","unstructured":"Song J.X.; Sze S.C.W.; Ng T.B.; Anti-Parkinsonian drug discovery from herbal medicines: What have we got from neurotoxic models? J Ethnopharmacol 2012,139(3),698-711","journal-title":"J Ethnopharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12640-017-9778-x","volume":"32","author":"Vijayanathan Y.","year":"2017","unstructured":"Vijayanathan Y.; Lim F.T.; Lim S.M.; 6-OHDA-lesioned adult zebrafish as a useful Parkinson\u2019s disease model for dopaminergic neu-roregeneration. Neurotox Res 2017,32(3),496-508","journal-title":"Neurotox Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000295666","volume":"7","author":"Schapira A.H.V.","year":"2010","unstructured":"Schapira A.H.V.; Future strategies for neuroprotection in Parkinson\u2019s disease. Neurodegener Dis 2010,7(1-3),210-212","journal-title":"Neurodegener Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neulet.2013.02.069","volume":"543","author":"Chong C.M.","year":"2013","unstructured":"Chong C.M.; Zhou Z.Y.; Razmovski-Naumovski V.; Danshensu protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Neurosci Lett 2013,543,121-125","journal-title":"Neurosci Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jep.2010.11.011","volume":"133","author":"Foyet H.S.","year":"2011","unstructured":"Foyet H.S.; Hritcu L.; Ciobica A.; Stefan M.; Kamtchouing P.; Cojocaru D.; Methanolic extract of Hibiscus asper leaves improves spatial memory deficits in the 6-hydroxydopamine-lesion rodent model of Parkinson\u2019s disease. J Ethnopharmacol 2011,133(2),773-779","journal-title":"J Ethnopharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cbi.2016.02.014","volume":"249","author":"Serratos I.N.","year":"2016","unstructured":"Serratos I.N.; Castellanos P.; Pastor N.; Early expression of the receptor for advanced glycation end products in a toxic model pro-duced by 6-hydroxydopamine in the rat striatum. Chem Biol Interact 2016,249,10-18","journal-title":"Chem Biol Interact"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1472-6882-14-142","volume":"14","author":"Beppe G.J.","year":"2014","unstructured":"Beppe G.J.; Dongmo A.B.; Foyet H.S.; Memory-enhancing activities of the aqueous extract of Albizia adianthifolia leaves in the 6-hydroxydopamine-lesion rodent model of Parkinson\u2019s disease. BMC Complement Altern Med 2014,14(1),142","journal-title":"BMC Complement Altern Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/jnc.14019","volume":"141","author":"Cruces-Sande A.","year":"2017","unstructured":"Cruces-Sande A.; M\u00e9ndez-\u00c1lvarez E.; Soto-Otero R.; Copper increases the ability of 6-hydroxydopamine to generate oxidative stress and the ability of ascorbate and glutathione to potentiate this effect: Potential implications in Parkinson\u2019s disease. J Neurochem 2017,141(5),738-749","journal-title":"J Neurochem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.taap.2011.07.021","volume":"256","author":"Latchoumycandane C.","year":"2011","unstructured":"Latchoumycandane C.; Anantharam V.; Jin H.; Kanthasamy A.; Kanthasamy A.; Dopaminergic neurotoxicant 6-OHDA induces oxidative damage through proteolytic activation of PKC\u03b4 in cell culture and animal models of Parkinson\u2019s disease. Toxicol Appl Pharmacol 2011,256(3),314-323","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.nrl.2015.06.011","volume":"32","author":"Hernandez-Baltazar D.","year":"2017","unstructured":"Hernandez-Baltazar D.; Zavala-Flores L.M.; Villanueva-Olivo A.; The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model. Neurologia 2017,32(8),533-539","journal-title":"Neurologia"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fnbeh.2018.00039","volume":"12","author":"Boix J.","year":"2018","unstructured":"Boix J.; von Hieber D.; Connor B.; Gait analysis for early detection of motor symptoms in the 6-ohda rat model of parkinson\u2019s disease. Front Behav Neurosci 2018,12,39","journal-title":"Front Behav Neurosci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2005.02.023","volume":"162","author":"Iancu R.","year":"2005","unstructured":"Iancu R.; Mohapel P.; Brundin P.; Paul G.; Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson\u2019s disease in mice. Behav Brain Res 2005,162(1),1-10","journal-title":"Behav Brain Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jneumeth.2004.10.004","volume":"144","author":"Yuan H.","year":"2005","unstructured":"Yuan H.; Sarre S.; Ebinger G.; Michotte Y.; Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson\u2019s disease. J Neurosci Methods 2005,144(1),35-45","journal-title":"J Neurosci Methods"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1471-4159.2004.02190.x","volume":"88","author":"Anichtchik O.V.","year":"2004","unstructured":"Anichtchik O.V.; Kaslin J.; Peitsaro N.; Scheinin M.; Panula P.; Neurochemical and behavioural changes in zebrafish Danio rerio after sys-temic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 2004,88(2),443-453","journal-title":"J Neurochem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s43440-020-00136-9","volume":"73","author":"Kozio\u0142 E.","year":"2021","unstructured":"Kozio\u0142 E.; Skalicka-Wo\u017aniak K.; Michalak A.; Kaszubska K.; Budzy\u0144ska B.; Xanthotoxin reverses Parkinson\u2019s disease-like symptoms in zebrafish larvae and mice models: A comparative study. Pharmacol Rep 2021,73(1),122-129","journal-title":"Pharmacol Rep"},{"key":"ref=52","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.172828","volume":"189","author":"Vaz R.L.","year":"2020","unstructured":"Vaz R.L.; Sousa S.; Chapela D.; Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model. Pharmacol Biochem Behav 2020,189","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuroscience.2017.10.018","volume":"367","author":"Cronin A.","year":"2017","unstructured":"Cronin A.; Grealy M.; Neuroprotective and neuro-restorative effects of minocycline and rasagiline in a zebrafish 6-hydroxydopamine model of Parkinson\u2019s disease. Neuroscience 2017,367,34-46","journal-title":"Neuroscience"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jtherbio.2010.12.005","volume":"36","author":"L\u00f3pez-Olmeda J.F.","year":"2011","unstructured":"L\u00f3pez-Olmeda J.F.; S\u00e1nchez-V\u00e1zquez F.J.; Thermal biology of zebrafish (Danio rerio). J Therm Biol 2011,36(2),91-104","journal-title":"J Therm Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ntt.2011.07.007","volume":"33","author":"Rico E.P.","year":"2011","unstructured":"Rico E.P.; Rosemberg D.B.; Seibt K.J.; Capiotti K.M.; Da Silva R.S.; Bonan C.D.; Zebrafish neurotransmitter systems as potential pharmacologi-cal and toxicological targets. Neurotoxicol Teratol 2011,33(6),608-617","journal-title":"Neurotoxicol Teratol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bbr.2011.01.019","volume":"219","author":"Mathur P.","year":"2011","unstructured":"Mathur P.; Guo S.; Differences of acute versus chronic ethanol exposure on anxiety-like behavioral responses in zebrafish. Behav Brain Res 2011,219(2),234-239","journal-title":"Behav Brain Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pbb.2015.05.014","volume":"135","author":"Magno L.D.P.","year":"2015","unstructured":"Magno L.D.P.; Fontes A.; Gon\u00e7alves B.M.N.; Gouveia A.; Pharmacological study of the light\/dark preference test in zebrafish (Danio rerio): Waterborne administration. Pharmacol Biochem Behav 2015,135,169-176","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fnagi.2017.00358","volume":"9","author":"Hou L.","year":"2017","unstructured":"Hou L.; Chen W.; Liu X.; Qiao D.; Zhou F.M.; Exercise-induced neuroprotection of the nigrostriatal dopamine system in Parkinson\u2019s dis-ease. Front Aging Neurosci 2017,9,358","journal-title":"Front Aging Neurosci"},{"key":"ref=59","first-page":"1189","volume":"7","author":"Fu W.","year":"2015","unstructured":"Fu W.; Zhuang W.; Zhou S.; Wang X.; Plant-derived neuroprotective agents in Parkinson\u2019s disease. Am J Transl Res 2015,7(7),1189-1202","journal-title":"Am J Transl Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00702-019-02115-8","volume":"127","author":"Salamon A.","year":"2020","unstructured":"Salamon A.; Z\u00e1dori D.; Szpisjak L.; Kliv\u00e9nyi P.; V\u00e9csei L.; Neuroprotection in Parkinson\u2019s disease: Facts and hopes. J Neural Transm 2020,127(5),821-829","journal-title":"J Neural Transm"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pneurobio.2015.10.004","volume":"155","author":"Reglodi D.","year":"2017","unstructured":"Reglodi D.; Renaud J.; Tamas A.; Novel tactics for neuroprotection in Parkinson\u2019s disease: Role of antibiotics, polyphenols and neu-ropeptides. Prog Neurobiol 2017,155,120-148","journal-title":"Prog Neurobiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.05.010","volume":"144","author":"Tarazi F.I.","year":"2014","unstructured":"Tarazi F.I.; Sahli Z.T.; Wolny M.; Mousa S.A.; Emerging therapies for Parkinson\u2019s disease: From bench to bedside. Pharmacol Ther 2014,144(2),123-133","journal-title":"Pharmacol Ther"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"10608","DOI":"10.3390\/ijms130810608","volume":"13","author":"Koppula S.","year":"2012","unstructured":"Koppula S.; Kumar H.; More S.V.; Kim B.W.; Kim I.S.; Choi D.K.; Recent advances on the neuroprotective potential of antioxidants in experi-mental models of Parkinson\u2019s disease. Int J Mol Sci 2012,13(8),10608-10629","journal-title":"Int J Mol Sci"},{"key":"ref=64","first-page":"91","volume":"3","author":"Sen S.","year":"2010","unstructured":"Sen S.; Chakraborty R.; Sridhar C.; Free radicals, antioxidants, diseases and phytomedicines: Current status and future prospect. Int J Pharm Sci Rev Res 2010,3(1),91-100","journal-title":"Int J Pharm Sci Rev Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10787-017-0402-8","volume":"26","author":"Sharma N.","year":"2018","unstructured":"Sharma N.; Nehru B.; Curcumin affords neuroprotection and inhibits \u03b1-synuclein aggregation in lipopolysaccharide-induced Parkinson\u2019s disease model. Inflammopharmacology 2018,26(2),349-360","journal-title":"Inflammopharmacology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.taap.2011.06.001","volume":"256","author":"Milatovic D.","year":"2011","unstructured":"Milatovic D.; Gupta R.C.; Yu Y.; Zaja-Milatovic S.; Aschner M.; Protective effects of antioxidants and anti-inflammatory agents against man-ganese-induced oxidative damage and neuronal injury. Toxicol Appl Pharmacol 2011,256(3),219-226","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1742-2094-9-241","volume":"9","author":"Ghosh A.","year":"2012","unstructured":"Ghosh A.; Kanthasamy A.; Joseph J.; Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson\u2019s disease. J Neuroinflammation 2012,9(1),241","journal-title":"J Neuroinflammation"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/foods10030586","volume":"10","author":"Sergi D.","year":"2021","unstructured":"Sergi D.; G\u00e9linas A.; Beaulieu J.; Anti-apoptotic and anti-inflammatory role of trans \u03b5-viniferin in a neuron\u2013glia co-culture cellular model of Parkinson\u2019s disease. Foods 2021,10(3),586","journal-title":"Foods"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.biopha.2016.11.074","volume":"85","author":"Abushouk A.I.","year":"2017","unstructured":"Abushouk A.I.; Negida A.; Ahmed H.; Abdel-Daim M.M.; Neuroprotective mechanisms of plant extracts against MPTP induced neurotoxici-ty: Future applications in Parkinson\u2019s disease. Biomed Pharmacother 2017,85,635-645","journal-title":"Biomed Pharmacother"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jns.2009.08.025","volume":"289","author":"L\u00f6hle M.","year":"2010","unstructured":"L\u00f6hle M.; Reichmann H.; Clinical neuroprotection in Parkinson\u2019s disease \u2014 Still waiting for the breakthrough. J Neurol Sci 2010,289(1-2),104-114","journal-title":"J Neurol Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1021\/cn400106n","volume":"4","author":"Santra S.","year":"2013","unstructured":"Santra S.; Xu L.; Shah M.; Johnson M.; Dutta A.; D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuro-protection properties and evaluation of in vivo efficacy in a Parkinson\u2019s disease animal model. ACS Chem Neurosci 2013,4(10),1382-1392","journal-title":"ACS Chem Neurosci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11030-013-9490-6","volume":"18","author":"Carradori S.","year":"2014","unstructured":"Carradori S.; D\u2019Ascenzio M.; Chimenti P.; Secci D.; Bolasco A.; Selective MAO-B inhibitors: A lesson from natural products. Mol Divers 2014,18(1),219-243","journal-title":"Mol Divers"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40263-015-0249-8","volume":"29","author":"Robakis D.","year":"2015","unstructured":"Robakis D.; Fahn S.; Defining the role of the monoamine oxidase-B inhibitors for Parkinson\u2019s disease. CNS Drugs 2015,29(6),433-441","journal-title":"CNS Drugs"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1021\/acs.jafc.6b03529","volume":"64","author":"Carradori S.","year":"2016","unstructured":"Carradori S.; Gidaro M.C.; Petzer A.; Inhibition of human monoamine oxidase: Biological and molecular modeling studies on selected natural flavonoids. J Agric Food Chem 2016,64(47),9004-9011","journal-title":"J Agric Food Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2010.01.013","volume":"291","author":"Ohta K.","year":"2010","unstructured":"Ohta K.; Kuno S.; Inoue S.; Ikeda E.; Fujinami A.; Ohta M.; The effect of dopamine agonists: The expression of GDNF, NGF, and BDNF in cultured mouse astrocytes. J Neurol Sci 2010,291(1-2),12-16","journal-title":"J Neurol Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cytogfr.2011.05.001","volume":"22","author":"Sullivan A.M.","year":"2011","unstructured":"Sullivan A.M.; Toulouse A.; Neurotrophic factors for the treatment of Parkinson\u2019s disease. Cytokine Growth Factor Rev 2011,22(3),157-165","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"184: 237-64","DOI":"10.1016\/S0079-6123(10)84013-0","author":"Rangasamy S.B.","year":"2010","unstructured":"Rangasamy S.B.; Soderstrom K.; Bakay R.A.E.; Kordower J.H.;  Neurotrophic factor therapy for Parkinson\u2019s disease Prog Brain Res 2010,184: 237-64","journal-title":"Neurotrophic factor therapy for Parkinson\u2019s disease Prog Brain Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2016.02.017","volume":"363","author":"da Silva P.G.C.","year":"2016","unstructured":"da Silva P.G.C.; Domingues D.D.; de Carvalho L.A.; Allodi S.; Correa C.L.; Neurotrophic factors in Parkinson\u2019s disease are regulated by exer-cise: Evidence-based practice. J Neurol Sci 2016,363,5-15","journal-title":"J Neurol Sci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10571-011-9731-0","volume":"32","author":"Zhang Z.J.","year":"2012","unstructured":"Zhang Z.J.; Cheang L.C.V.; Wang M.W.; Ethanolic extract of fructus Alpinia oxyphylla protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Cell Mol Neurobiol 2012,32(1),27-40","journal-title":"Cell Mol Neurobiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/antiox9040304","volume":"9","author":"Abidar S.","year":"2020","unstructured":"Abidar S.; Boiangiu R.; Dumitru G.; The aqueous extract from ceratonia siliqua leaves protects against 6-hydroxydopamine in zebrafish: Understanding the underlying mechanism. Antioxidants 2020,9(4),304","journal-title":"Antioxidants"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.37358\/RC.18.12.6788","volume":"69","author":"Dumitru G.","year":"2019","unstructured":"Dumitru G.; Abidar S.; Nhiri M.; Effect of ceratonia siliqua methanolic extract and 6-hydroxydopamine on memory impairment and oxidative stress in zebrafish (Danio rerio) model. Revista de Chimie 2019,69(12),3545-3548","journal-title":"Revista de Chimie"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.37358\/RC.19.4.7128","volume":"70","author":"Hritcu L.","year":"2019","unstructured":"Hritcu L.; Abidar S.; Dumitru G.; Ceratonia siliqua methanolic extract on 6-OHDA zebrafish model antiacetylcholinesterase and anxiolytic profile. Revista de Chimie 2019,70(4),1364-1367","journal-title":"Revista de Chimie"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jpha.2020.06.002","volume":"11","author":"Yu D.","year":"2021","unstructured":"Yu D.; Zhang P.; Li J.; Neuroprotective effects of Ginkgo biloba dropping pills in Parkinson\u2019s disease. J Pharm Anal 2021,11(2),220-231","journal-title":"J Pharm Anal"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1017\/cjn.2017.268","volume":"45","author":"Kuang S.","year":"2018","unstructured":"Kuang S.; Yang L.; Rao Z.; Effects of Ginkgo biloba extract on A53T \u03b1-synuclein transgenic mouse models of Parkinson\u2019s disease. Can J Neurol Sci 2018,45(2),182-187","journal-title":"Can J Neurol Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.cct.2006.02.007","volume":"27","author":"DeKosky S.T.","year":"2006","unstructured":"DeKosky S.T.; Fitzpatrick A.; Ives D.G.; The Ginkgo Evaluation of Memory (GEM) study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 2006,27(3),238-253","journal-title":"Contemp Clin Trials"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/7571629","volume":"2018","author":"Sun M.","year":"2018","unstructured":"Sun M.; Chai L.; Lu F.; Efficacy and safety of Ginkgo Biloba pills for coronary heart disease with impaired glucose regulation: Study protocol for a series of n-of-1 randomized, double-blind, placebo-controlled trials. Evid Based Complement Alternat Med 2018,2018,1-8","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fct.2018.06.018","volume":"119","author":"Li M.","year":"2018","unstructured":"Li M.; Zhou F.; Xu T.; Song H.; Lu B.; Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway. Food Chem Toxicol 2018,119,6-13","journal-title":"Food Chem Toxicol"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162696","volume":"11","author":"Yuan J.","year":"2016","unstructured":"Yuan J.; Ren J.; Wang Y.; He X.; Zhao Y.; Acteoside binds to caspase-3 and exerts neuroprotection in the rotenone rat model of Parkinson\u2019s disease. PLoS One 2016,11(9)","journal-title":"PLoS One"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174136","volume":"903","author":"Aimaiti M.","year":"2021","unstructured":"Aimaiti M.; Wumaier A.; Aisa Y.; Acteoside exerts neuroprotection effects in the model of Parkinson\u2019s disease via inducing autopha-gy: Network pharmacology and experimental study. Eur J Pharmacol 2021,903","journal-title":"Eur J Pharmacol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1021\/acs.jproteome.6b00152","volume":"15","author":"Li G.","year":"2016","unstructured":"Li G.; Zhang Z.; Quan Q.; Discovery, synthesis, and functional characterization of a novel neuroprotective natural product from the fruit of Alpinia oxyphylla for use in Parkinson\u2019s disease through LC\/MS-based multivariate data analysis-guided fractionation. J Proteome Res 2016,15(8),2595-2606","journal-title":"J Proteome Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"559","DOI":"10.14336\/AD.2019.0612","volume":"11","author":"Zhou H.","year":"2020","unstructured":"Zhou H.; Li S.; Li C.; Oxyphylla A promotes degradation of \u03b1-synuclein for neuroprotection via activation of immunoproteasome. Aging Dis 2020,11(3),559-574","journal-title":"Aging Dis"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neulet.2010.09.038","volume":"486","author":"Kwon I.H.","year":"2010","unstructured":"Kwon I.H.; Choi H.S.; Shin K.S.; Effects of berberine on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and a rat model of Parkinson\u2019s disease. Neurosci Lett 2010,486(1),29-33","journal-title":"Neurosci Lett"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.3892\/ijmm.2014.1656","volume":"33","year":"2014","unstructured":"Kim , Cho KH, Shin MS, et al. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson\u2019s disease. Int J Mol Med 2014,33(4),2870-89","journal-title":"Int J Mol Med"},{"key":"ref=94","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2019.104612","volume":"132","author":"Angelopoulou E.","year":"2020","unstructured":"Angelopoulou E.; Pyrgelis E.S.; Piperi C.; Neuroprotective potential of chrysin in Parkinson\u2019s disease: Molecular mechanisms and clinical implications. Neurochem Int 2020,132","journal-title":"Neurochem Int"},{"key":"ref=95","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134382","volume":"709","author":"Krishnamoorthy A.","year":"2019","unstructured":"Krishnamoorthy A.; Sevanan M.; Mani S.; Balu M.; Balaji S.; P R. Chrysin restores MPTP induced neuroinflammation, oxidative stress and neurotrophic factors in an acute Parkinson\u2019s disease mouse model. Neurosci Lett 2019,709","journal-title":"Neurosci Lett"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbi.2017.10.019","volume":"279","author":"Goes A.T.R.","year":"2018","unstructured":"Goes A.T.R.; Jesse C.R.; Antunes M.S.; Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson\u2019s disease: Involvement of neuroinflammation and neurotrophins. Chem Biol Interact 2018,279,111-120","journal-title":"Chem Biol Interact"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.neulet.2019.05.036","volume":"706","author":"Del Fabbro L.","year":"2019","unstructured":"Del Fabbro L.; Rossito Goes A.; Jesse C.R.; Chrysin protects against behavioral, cognitive and neurochemical alterations in a 6-hydroxydopamine model of Parkinson\u2019s disease. Neurosci Lett 2019,706,158-163","journal-title":"Neurosci Lett"},{"key":"ref=98","first-page":"35","volume":"12","author":"Ahmed M.R.","year":"2018","unstructured":"Ahmed M.R.; Shaikh M.A.; Ul Haq S.H.I.; Nazir S.; Neuroprotective role of chrysin in attenuating loss of dopaminergic neurons and improv-ing motor, learning and memory functions in rats. Int J Health Sci 2018,12(3),35-43","journal-title":"Int J Health Sci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1142\/S0192415X16500750","volume":"44","author":"Cui G.","year":"2016","unstructured":"Cui G.; Shan L.; Chen Y.; Zhou H.; Wang Y.; Lee S.M.Y.; A new Danshensu derivative protects against 6-hydroxydopamine-induced neuro-toxicity in vitro and in vivo. Am J Chin Med 2016,44(7),1349-1361","journal-title":"Am J Chin Med"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135426","volume":"740","author":"Kesh S.","year":"2021","unstructured":"Kesh S.; Kannan R.R.; Sivaji K.; Balakrishnan A.; Hesperidin downregulates kinases lrrk2 and gsk3\u03b2 in a 6-OHDA induced Parkinson\u2019s disease model. Neurosci Lett 2021,740","journal-title":"Neurosci Lett"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.nut.2014.03.024","volume":"30","author":"Antunes M.S.","year":"2014","unstructured":"Antunes M.S.; Goes A.T.R.; Boeira S.P.; Prigol M.; Jesse C.R.; Protective effect of hesperidin in a model of Parkinson\u2019s disease induced by 6-hydroxydopamine in aged mice. Nutrition 2014,30(11-12),1415-1422","journal-title":"Nutrition"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1007\/s12035-020-01940-3","volume":"57","author":"Antunes M.S.","year":"2020","unstructured":"Antunes M.S.; Cattelan Souza L.; Ladd F.V.L.; Hesperidin ameliorates anxiety-depressive-like behavior in 6-OHDA model of parkin-son\u2019s disease by regulating striatal cytokine and neurotrophic factors levels and dopaminergic innervation loss in the striatum of mice. Mol Neurobiol 2020,57(7),3027-3041","journal-title":"Mol Neurobiol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4103\/2231-0738.114875","volume":"3","author":"Manivasagam T.","year":"2013","unstructured":"Manivasagam T.; Nataraj J.; Tamilselvam K.; Essa M.M.; Janakiraman U.; Antioxidant and anti-inflammatory potential of hesperidin against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced experimental Parkinson\u2032s disease in mice. Int J Nutr Pharmacol Neurol Dis 2013,3(3),294","journal-title":"Int J Nutr Pharmacol Neurol Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cbi.2017.11.018","volume":"279","author":"Poetini M.R.","year":"2018","unstructured":"Poetini M.R.; Araujo S.M.; Trindade de Paula M.; Hesperidin attenuates iron-induced oxidative damage and dopamine depletion in Drosophila melanogaster model of Parkinson\u2019s disease. Chem Biol Interact 2018,279,177-186","journal-title":"Chem Biol Interact"},{"key":"ref=105","first-page":"930","volume":"9","author":"Rushdy H.","year":"2012","unstructured":"Rushdy H.; Rushdy H.; Salem A.; Influence of Hesperidin combined with Sinemet on genetical and biochemical abnormalities in rats suffering from Parkinson\u2019s disease. Life Sci J 2012,9(4),930-945","journal-title":"Life Sci J"},{"key":"ref=106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpc.2020.108893","volume":"239","author":"Kesh S.","year":"2021","unstructured":"Kesh S.; Kannan R.R.; Balakrishnan A.; Naringenin alleviates 6-hydroxydopamine induced Parkinsonism in SHSY5Y cells and zebrafish model. Comp Biochem Physiol C Toxicol Pharmacol 2021,239","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12640-018-9869-3","volume":"33","author":"Mani S.","year":"2018","unstructured":"Mani S.; Sekar S.; Barathidasan R.; Naringenin decreases \u03b1-synuclein expression and neuroinflammation in MPTP-induced Parkin-son\u2019s disease model in mice. Neurotox Res 2018,33,656-670","journal-title":"Neurotox Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/00207454.2018.1545772","volume":"129","author":"Sugumar M.","year":"2019","unstructured":"Sugumar M.; Sevanan M.; Sekar S.; Neuroprotective effect of naringenin against MPTP-induced oxidative stress. Int J Neurosci 2019,129(6),534-539","journal-title":"Int J Neurosci"},{"key":"ref=109","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108831","volume":"201","author":"Ahmad M.H.","year":"2021","unstructured":"Ahmad M.H.; Fatima M.; Ali M.; Rizvi M.A.; Mondal A.C.; Naringenin alleviates paraquat-induced dopaminergic neuronal loss in SH-SY5Y cells and a rat model of Parkinson\u2019s disease. Neuropharmacology 2021,201","journal-title":"Neuropharmacology"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.neuropharm.2013.11.026","volume":"79","author":"Lou H.","year":"2014","unstructured":"Lou H.; Jing X.; Wei X.; Shi H.; Ren D.; Zhang X.; Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2\/ARE signaling pathway. Neuropharmacology 2014,79,380-388","journal-title":"Neuropharmacology"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jep.2010.10.017","volume":"133","author":"Luo F.C.","year":"2011","unstructured":"Luo F.C.; Wang S.D.; Qi L.; Song J.Y.; Lv T.; Bai J.; Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo. J Ethnopharmacol 2011,133(2),448-453","journal-title":"J Ethnopharmacol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.freeradbiomed.2015.02.030","volume":"84","author":"Zhang Z.","year":"2015","unstructured":"Zhang Z.; Li G.; Szeto S.S.W.; Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease. Free Radic Biol Med 2015,84,331-343","journal-title":"Free Radic Biol Med"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.fct.2005.08.017","volume":"44","author":"An L.J.","year":"2006","unstructured":"An L.J.; Guan S.; Shi G.F.; Bao Y.M.; Duan Y.L.; Jiang B.; Protocatechuic acid from Alpinia oxyphylla against MPP+-induced neurotoxicity in PC12 cells. Food Chem Toxicol 2006,44(3),436-443","journal-title":"Food Chem Toxicol"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3892\/ijmm.2011.613","volume":"27","author":"Zhang Z.J.","year":"2011","unstructured":"Zhang Z.J.; Cheang L.C.V.; Wang M.W.; Lee S.M.; Quercetin exerts a neuroprotective effect through inhibition of the iNOS\/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish. Int J Mol Med 2011,27(2),195-203","journal-title":"Int J Mol Med"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/jnc.14033","volume":"141","author":"Ay M.","year":"2017","unstructured":"Ay M.; Luo J.; Langley M.; Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson\u2019s Disease. J Neurochem 2017,141(5),766-782","journal-title":"J Neurochem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/928643","volume":"2012","author":"Lv C.","year":"2012","unstructured":"Lv C.; Hong T.; Yang Z.; Effect of quercetin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkin-son\u2019s disease. Evid Based Complement Alternat Med 2012,2012,1-6","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.neuroscience.2013.01.032","volume":"236","author":"Karuppagounder S.S.","year":"2013","unstructured":"Karuppagounder S.S.; Madathil S.K.; Pandey M.; Haobam R.; Rajamma U.; Mohanakumar K.P.; Quercetin up-regulates mitochondrial com-plex-I activity to protect against programmed cell death in rotenone model of Parkinson\u2019s disease in rats. Neuroscience 2013,236,136-148","journal-title":"Neuroscience"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neulet.2011.06.021","volume":"500","author":"Haleagrahara N.","year":"2011","unstructured":"Haleagrahara N.; Siew C.J.; Mitra N.K.; Kumari M.; Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxida-tive stress biomarkers in the rat striatum. Neurosci Lett 2011,500(2),139-143","journal-title":"Neurosci Lett"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/823206","volume":"2012","author":"Sriraksa N.","year":"2012","unstructured":"Sriraksa N.; Wattanathorn J.; Muchimapura S.; Cognitive-enhancing effect of quercetin in a rat model of Parkinson\u2019s disease induced by 6-Hydroxydopamine. Evid Based Complement Alternat Med 2012,2012,1-9","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"Hickson L.J.","year":"2019","unstructured":"Hickson L.J.; Langhi Prata L.G.P.; Bobart S.A.; Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 2019,47,446-456","journal-title":"EBioMedicine"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.1016\/j.phanu.2020.100250","volume":"15","author":"Shatylo V.","year":"2021","unstructured":"Shatylo V.; Antoniuk-Shcheglova I.; Naskalova S.; Cardio-metabolic benefits of quercetin in elderly patients with metabolic syn-drome. PharmaNutrition 2021,15","journal-title":"PharmaNutrition"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jep.2015.04.040","volume":"170","author":"Zhang L.Q.","year":"2015","unstructured":"Zhang L.Q.; Sa F.; Chong C.M.; Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS\/NO and AKT\/GSK3\u03b2 pathways. J Ethnopharmacol 2015,170,8-15","journal-title":"J Ethnopharmacol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neulet.2015.03.016","volume":"593","author":"Sa F.","year":"2015","unstructured":"Sa F.; Zhang L.Q.; Chong C.M.; Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo. Neurosci Lett 2015,593,7-12","journal-title":"Neurosci Lett"},{"key":"ref=124","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2019.110743","volume":"128","author":"Yan T.","year":"2019","unstructured":"Yan T.; Sun Y.; Gong G.; The neuroprotective effect of schisandrol A on 6-OHDA-induced PD mice may be related to PI3K\/AKT and IKK\/I\u03baB\u03b1\/NF-\u03baB pathway. Exp Gerontol 2019,128","journal-title":"Exp Gerontol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neuint.2014.09.001","volume":"78","author":"Xu D.P.","year":"2014","unstructured":"Xu D.P.; Zhang K.; Zhang Z.J.; A novel tetramethylpyrazine bis-nitrone (TN-2) protects against 6-hydroxyldopamine-induced neuro-toxicity via modulation of the NF-\u03baB and the PKC\u03b1\/PI3-K\/Akt pathways. Neurochem Int 2014,78,76-85","journal-title":"Neurochem Int"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6688708","volume":"2021","author":"Wu W.","year":"2021","unstructured":"Wu W.; Han H.; Liu J.; Fucoxanthin prevents 6-OHDA-induced neurotoxicity by targeting keap1. Oxid Med Cell Longev 2021,2021,1-14","journal-title":"Oxid Med Cell Longev"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/md14100187","volume":"14","author":"Feng C.W.","year":"2016","unstructured":"Feng C.W.; Hung H.C.; Huang S.Y.; Neuroprotective effect of the marine-derived compound 11-dehydrosinulariolide through DJ-1-related pathway in in vitro and in vivo models of Parkinson\u2019s disease. Mar Drugs 2016,14(10),187","journal-title":"Mar Drugs"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00210-011-0710-2","volume":"385","author":"Chen W.F.","year":"2012","unstructured":"Chen W.F.; Chakraborty C.; Sung C.S.; Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkin-son\u2019s model: A promising candidate for the treatment of Parkinson\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 2012,385(3),265-275","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/ijms18051096","volume":"18","author":"Kao C.J.","year":"2017","unstructured":"Kao C.J.; Chen W.F.; Guo B.L.; The 1-tosylpentan-3-one protects against 6-hydroxydopamine-induced neurotoxicity. Int J Mol Sci 2017,18(5),1096","journal-title":"Int J Mol Sci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/md17060315","volume":"17","author":"Feng C.W.","year":"2019","unstructured":"Feng C.W.; Chen N.F.; Wen Z.H.; In vitro and in vivo neuroprotective effects of stellettin B through anti-apoptosis and the Nrf2\/HO-1 pathway. Mar Drugs 2019,17(6),315","journal-title":"Mar Drugs"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527322666221028152600","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210455\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527322666221028152600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:17:02Z","timestamp":1694603822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210455\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":130,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527322666221028152600","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}